摘要
目的:探讨三联幽门螺杆菌(helicobacter pylori,Hp)根除疗法与奥美拉唑、铝碳酸镁联合治疗胃溃疡的疗效。方法:选取2014年3月—2016年3月辽宁省荣军医院收治的Hp感染胃溃疡患者60例作为研究对象,按照随机数字表法分为观察组和对照组,每组各30例。2组患者在治疗的第1周均采用三联Hp根除疗法,对照组患者在三联Hp根除疗法的基础上给予奥美拉唑治疗,观察组患者在对照组的基础上给予铝碳酸镁治疗。比较2组患者的治疗效果、Hp根除率。结果:观察组患者治愈及显效率为83.3%(25/30),显著高于对照组的60.0%(18/30),差异有统计学意义(P<0.05);观察组患者Hp根除率、不良反应发生率分别为93.3%(28/30)、3.3%(1/30),均明显优于对照组的76.7%(23/30)、16.7%(5/30),差异均有统计学意义(P<0.05)。结论:三联Hp根除疗法与奥美拉唑、铝碳酸镁联合治疗胃溃疡,治愈率高,不良反应发生率低,Hp根除率高,具有良好的治疗效果。
OBJECTIVE: To probe into the efficacy of rabeprazole triple therapy of Helicobacter pylori( Hp)eradication combined with omeprazole and hydrotalcite in treatment of gastric ulcer. METHODS: 60 cases admitted into Liaoning Rongjun Hospital from Mar. 2014 to Mar. 2016 were selected to be divided into observation group and control group via the random number table,with 30 cases in each. Two group of patients were treated with rabeprazole triple therapy of Hp eradication,and based on which the control group additionally received omeprazole,while the observation group were additionally treated with hydrotalcite based on the control group. The treatment effects,Hp eradication rate were compared between two groups. RESULTS: The cure and excellence rate of observation group was83. 3%( 25 /30),significantly higher than that of control group [60. 0%( 18 /30) ],with statistically significant difference( P〈0. 05). The Hp eradication rate,incidence of adverse drug reactions in observation group were respectively 93. 3%( 28 /30) and 3. 3%( 1 /30),significantly higher than those of control group [76. 7%( 23 /30)and 16. 7%( 5 /30) ],with statistically significant difference( P〈0. 05). CONCLUSIONS: The efficacy of rabeprazole triple therapy of Hp eradication combined with omeprazole and hydrotalcite in treatment of gastric ulcer is significant,with high cure rate,low incidence of adverse drug reactions and high Hp eradication.
出处
《中国医院用药评价与分析》
2016年第11期1492-1493,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
三联Hp根除疗法
奥美拉唑
铝碳酸镁
胃溃疡
可行性
Rabeprazole triple therapy of helicobacter pylori eradication
Omeprazole
Hydrotalcite
Gastric ulcer
Feasibility